Seòmar agus comataidhean

The Cabinet Secretary for the Constitution, External Affairs and Culture and I meet regularly with Creative Scotland to discuss our shared priorities, including funding for cultural organisations during the cost of living crisis which was discussed at the most recent meetings in June and October.

The Scottish Government is in regular dialogue with the sector, and will continue to work with it to identify barriers to immediate and long-term recovery, and to do everything within our powers and resources to help those most affected by current economic challenges.

The Cabinet Secretary for the Constitution, External Affairs and Culture and I hosted a virtual roundtable with public bodies and representative groups on 10 November. The Scottish Government will be hosting further roundtable discussions with the sector this winter.

Digital pathology services have traditionally been the responsibility of individual Health Boards. Recognising the potential for a national approach, a Digital Diagnostics Group was established in April 2022 by the Scottish Government. This group is providing strategic oversight for a number of diagnostic services, including pathology services.

The first phase of this national approach has seen investment of £777,000 during 2022-23 provided to NHS Ayrshire & Arran, NHS Greater Glasgow and Clyde and NHS Highland. These three Board's are currently at the implementation stage and the learning from this work will shape plans for a national rollout across all boards in Scotland from 2023-24 onwards.

We are developing a new 10 year cancer strategy to launch in Spring 2023, which will take a comprehensive approach to improving patient pathways from prevention and diagnosis through to treatment and post-treatment care.

Blood cancer charities have been engaged throughout the development of the cancer strategy including responding to the public consultation (to which there were a total of over 250 responses) and in further meetings with the Third Sector.

Yes, as set out in our recent Waste and Circular Economy Route Map consultation, we intend to set new circular economy targets for the period to 2030 which go beyond weight-based criteria.

We must ensure that any future targets correspond to our Environment Strategy and overall vision for a circular economy, alongside the principles we set out in the consultation. One of these key principles is that any future targets should help to ensure that we deliver a sustainable international material footprint.

The feedback from the First Minister’s Environmental Council will be considered along with responses to the Route Map consultation, which are currently being analysed.

The Scottish Government have allocated £1 million to support local authorities to date to cover the costs of welcome activities, such as access to meals, translation services and trauma support. We recognise that costs arising may go beyond the £1 million initially made available, and we are working with COSLA and local authorities to ensure that reasonable costs associated with the super sponsor scheme are met by the Scottish Government. The full costs are yet to be determined.

To date, just under £6.1 million has been paid out under the fund. It is worth noting that grants awarded by the Knowledge Transfer and Innovation Fund (KTIF) are drawn down by recipients in arrears. As such, the fund is scheduled to pay out an additional £1.4 million under its current commitments.

The KTIF awards funding to a range of national organisations operating across a wide range of local authorities in Scotland. Therefore, a breakdown is not appropriate or something officials can offer to give an accurate distribution of funding across the authorities.

The decision not to procure Evusheld ® at this time has been taken based on clinical advice, rather cost.

The RAPID C-19 group is a collaborative UK-wide partnership between the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and others. To date, the RAPID C-19 group and the COVID-19 UK expert panel have both considered a full range of evidence, including clinical trial data, in vitro (in the laboratory) analysis and observational studies and have advised that there is insufficient evidence available at this time to support the procurement and deployment of Evusheld ® .

The Scottish Government continues to closely monitor the outcome of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence.

The Scottish Government continues to closely monitor the outcomes of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence. The RAPID C-19 group is a collaborative UK-wide partnership between the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and others. To date, the RAPID C-19 group and the COVID-19 UK expert panel have both considered a full range of evidence, including clinical trial data, in vitro (in the laboratory) analysis and observational studies and have advised that there is insufficient evidence available at this time to support the procurement and deployment of Evusheld ® .

The RAPID C-19 group is keeping this position under active review, including through monitoring any emerging data. Building on the work of the RAPID C-19 group, the SMC is exploring the potential for collaboration with NICE on a single technology assessment (STA) of tixagevimab–cilgavimab (Evusheld ® ) for the prevention of COVID-19. In order to gain further evidence, consideration is also being given to establishing a clinical trial as a route to answering outstanding questions on the link between in vitro tests and clinical outcomes for current and future variants, which is currently not known. The trial may also assist with evaluating the effectiveness and safety of a higher dose of 600mg, which is now being used in a number of countries, which have previously purchased Evusheld®, as this was not tested in the company’s randomised controlled trials.

I have recently written to the UK Government supporting the establishment of a clinical trial and stating my wish to see individuals in Scotland included.

Electricity policy, including regulation of Great Britain’s electricity networks, is an area reserved to the UK Government.

In order to meet our net zero targets both increased renewable generation and network investment will be required. We are working to expand our renewable generation capabilities through our continued support for renewable technologies.

The Scottish Government, however, does not have the power to ensure that sufficient network investment will be taken forward. We have repeatedly called on Ofgem and BEIS to ensure that network companies can invest to ready the network for the requirements of transitioning to net zero.

The Scottish Government has also invested over £65 million in ChargePlace Scotland, Scotland’s public charging network, which now has more than 2300 publicly available charge points meaning that, by population, Scotland has the most EV charge points outside of London and the most rapid charge points anywhere in the UK.

The Scottish Government is committed to exploring the implementation of HPV self-sampling, and acknowledges that it has the potential to increase uptake levels and reduce barriers to cervical screening.

The UK National Screening Committee (NSC) recognises the potential benefits of self-sampling but have concluded that there is currently insufficient evidence to recommend implementation. Studies are underway to gather further evidence, but it is not yet known when the NSC may make a positive recommendation. Additionally, it is unclear when the work to assess and validate a test for HPV self-sampling in the UK will complete.

As introducing a new screening test into the National Screening Programme is inherently complex, a working group has been convened to assess potential models and understand any required changes to the screening programme to support an initial roll-out. This work is being informed by the emerging evidence from UK and global research, including the study undertaken in Dumfries and Galloway which provided self-sampling test kits to women between 25 and 64 who had not taken up the offer of attending for cervical screening. The results of this study showed the potential benefits of self-sampling, but also underlined the need to carefully consider how any eventual roll-out is targeted.